Endocrinology
News
FDA adds diabetic kidney disease, heart failure indications to canagliflozin
This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.
News
Machine learning–derived risk score predicts heart failure risk in diabetes patients
Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%.
Video
DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug
News
Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CAD
Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy.
News
Dapagliflozin meets primary endpoint in the DAPA-HF trial
AstraZeneca announces preliminary results in first heart failure trial in an SGLT2 inhibitor.
News
New biomarker model outmatches conventional risk factors for predicting mortality
Although the majority of these biomarkers have been associated with mortality before, this is the first study that shows their independent effect...
News
FDA approves Baqsimi nasal powder for emergency hypoglycemia treatment
It is the first glucagon therapy approved for this indication that is administrable without an injection.
News
FDA issues warning on insulin pump cybersecurity weakness
The MiniMed 508 and MiniMed Paradigm series insulin pumps are being recalled because of potential cybersecurity risks; 4,000 patients in the...
Clinical
Aspirin shows little benefit for primary prevention of vascular disease in diabetes
Is aspirin for primary prevention of cardiovascular events in patients with diabetes worth the risk of adverse bleeding events?
News
SGLT2 inhibitors prevent HF hospitalization regardless of baseline LVEF
NEW ORLEANS – “At least in my mind, we have more than enough evidence at this point to say that SGLT2 inhibitors are effective in preventing heart...